John Shulman - Petros Pharmaceuticals Executive Board
| PTPI Stock | USD 0.27 0.01 3.85% |
Executive
John Shulman is Executive Board of Petros Pharmaceuticals
| Age | 61 |
| Address | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
| Phone | 973 242 0005 |
| Web | https://www.petrospharma.com |
John Shulman Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Shulman against Petros Pharmaceuticals stock is an integral part of due diligence when investing in Petros Pharmaceuticals. John Shulman insider activity provides valuable insight into whether Petros Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Petros Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Petros Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Shulman over two weeks ago Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3 | ||
John Shulman over a month ago Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3 |
Petros Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3061) % which means that it has lost $0.3061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6377) %, meaning that it created substantial loss on money invested by shareholders. Petros Pharmaceuticals' management efficiency ratios could be used to measure how well Petros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.35. The current Return On Capital Employed is estimated to decrease to -0.62. As of now, Petros Pharmaceuticals' Non Current Assets Total are decreasing as compared to previous years. The Petros Pharmaceuticals' current Non Currrent Assets Other is estimated to increase to about 6.2 M, while Other Assets are projected to decrease to under 9.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eddie MBA | Lumos Pharma | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David Ege | Seres Therapeutics | 49 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Lisa MD | Seres Therapeutics | 65 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 |
Petros Pharmaceuticals Leadership Team
Elected by the shareholders, the Petros Pharmaceuticals' board of directors comprises two types of representatives: Petros Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Petros. The board's role is to monitor Petros Pharmaceuticals' management team and ensure that shareholders' interests are well served. Petros Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Petros Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fady MBA, President Officer | ||
| Mitchell MBA, VP Officer | ||
| Keith Lavan, Advisor | ||
| John Shulman, Executive Board | ||
| Robert Weinstein, Interim Officer |
Petros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Petros Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.60) % | ||||
| Current Valuation | 26.75 M | ||||
| Shares Outstanding | 10.01 M | ||||
| Shares Owned By Insiders | 8.10 % | ||||
| Shares Owned By Institutions | 2.20 % | ||||
| Number Of Shares Shorted | 199.19 K | ||||
| Price To Book | 0.87 X |
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.